Navigation Links
Nexavar Data to be Presented at 46th American Society of Clinical Oncology Annual Meeting
Date:5/20/2010

nd individual investigators as a single agent or as a combination treatment in a wide range of cancers, including lung, thyroid, breast, ovarian, and colorectal cancer and as an adjuvant therapy for liver and kidney cancer. 

Important Safety Considerations For Patients Taking Nexavar

Based on the currently approved U.S. package insert for the treatment of patients with unresectable hepatocellular carcinoma and advanced kidney cancer, hypertension may occur early in the course of therapy and blood pressure should be monitored weekly during the first six weeks of therapy and treated as needed.  In HCC patients, bleeding with a fatal outcome from any site was reported in 2.4% for Nexavar and 4% in placebo.  The incidence of treatment-emergent cardiac ischemia/infarction was 2.7% for Nexavar vs. 1.3% for placebo.  In RCC patients, incidence of bleeding regardless of causality was 15% for Nexavar vs. 8% for placebo and the incidence of treatment-emergent cardiac ischemia/infarction was 2.9% for Nexavar vs. 0.4% for placebo.  Most common adverse events >/=20% related to Nexavar for both HCC and RCC were fatigue, weight loss, rash/desquamation, hand-foot skin reaction, alopecia, diarrhea, nausea, and abdominal pain.  Grade 3/4 adverse events in HCC and RCC patients, respectively, were 45% for Nexavar vs. 32% for placebo and 38% for Nexavar and 28% for placebo.  Women of child-bearing potential should be advised to avoid becoming pregnant and advised against breast-feeding.  In cases of any severe or persistent side effects, temporary treatment interruption, dose modification or permanent discontinuation should be considered.

For information about Nexavar including U.S. Nexavar prescribing information, visit

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
2. Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting
3. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar
4. Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting
5. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
6. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
7. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
8. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
9. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
10. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
11. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... and TORONTO, March 3, 2015 /PRNewswire/ - Aptose Biosciences ... new therapeutics and molecular diagnostics that target the underlying ... quarter and seventh-month period ended December 31, 2014. ... fiscal year end from May 31 to December 31. ... are reporting today are for the quarter and the ...
(Date:3/3/2015)... , March 3, 2015 NASA astronaut ... launch this month to spend a year living and working ... satellite interviews from 5:30 to 7 a.m. EDT Monday, March ... as he completes the final weeks of his ... a video on NASA Television highlighting his mission training and ...
(Date:3/3/2015)... Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced several new ... in North America , the Middle ... "Bidding activity in 2015 continues to be robust" said Derek ... for bidding in 2014, we are pleased to see the bidding ... organization,s renewed focus on select market segments where we can add ...
(Date:3/3/2015)... , March 3, 2015  Neurocrine Biosciences, Inc. ... Kevin Gorman , President and Chief Executive Officer of ... Healthcare Conference in Miami.   The live ... ET (7:15am PT).  The presentation will be webcast and ... http://www.neurocrine.com .   Listeners are encouraged to ...
Breaking Biology Technology:Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12NASA Astronaut Scott Kelly Available for Interviews before One-Year Space Station Mission 2
... Bulletin Board:,NTRZ), a world leader in stabilized rice ... it has appointed Olga Hernandez-Longan [45],to the position ... with,his previously announced intentions, has retired as CFO, ... capacity., Ms. Hernandez-Longan has over 20 years ...
... higher revenue due to Roche milestone -, BRISBANE, Calif., ... results from operations for the third,quarter and nine months ended ... quarter of 2008 of $12.5 million, or $0.32 per share,compared ... share, in the third,quarter of 2007., Dan Welch, Chairman, ...
... Nov. 6 ViroPharma Incorporated,(Nasdaq: VPHM ) ... officer of ViroPharma, will present at the Rodman ... ET on Wednesday, November,12, 2008. The conference is ... ViroPharma also announced that Colin Broom, vice ...
Cached Biology Technology:NutraCea Appoints New Chief Financial Officer 2InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 2InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 3InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 4InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 5InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 6InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 7InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 8InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 9ViroPharma to Present at Three November Healthcare Conferences 2
(Date:2/5/2015)... 2015 New Market Research Reports ... Forecasts To 2020 has Been Added to GrandViewReseach.com Report ... expected to reach USD 5.10 billion by 2020, according ... IR cameras help identify the site of tissue damage ... surging demand in medical imaging applications. They have been ...
(Date:2/5/2015)...  It is gratifying to see that the Obama ... science as a means to better understand human biology, ... was honored to participate in today,s White House event ... Since the 1980s my teams have been ... sequenced genome of a free living organism, the first ...
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to ... State of Washington,s Department of Licensing, in ... central issuance system for driver,s licenses and identification cards to ... and development will start in January 2015, with enrollment and ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Valid USA Signs Contract For Washington Driver's License Issuance 2
... Oct. 27, 2009 UT Southwestern Medical Center patient ... receive the newest generation of a mechanical device designed to ... awaits a heart transplant. Called a left-ventricular assist device ... pump blood throughout the body. For Mr. LeBlanc, it will ...
... 45 percent of blood, normally take the shape of circular ... sometimes deform into an asymmetrical slipper shape. A team ... might be responsible for this deformation, as well as how ... help understand the mechanisms involved in arterial disease and other ...
... nest? Early in development infants of many species experience ... presence of their mother to start exploring the wider ... the brain during that turning point. Based on ... strength of attachments in many speciesincluding the conundrum of ...
Cached Biology News:UT Southwestern patient first in North Texas to receive newest-generation heart failure device 2UT Southwestern patient first in North Texas to receive newest-generation heart failure device 3Changes in brain chemicals mark shifts in infant learning 2Changes in brain chemicals mark shifts in infant learning 3
MAb to Mouse MHC Class I H-2Kd...
... Gel-Digesting Preparation contains a unique β-agarose digesting ... recovery of intact DNA and RNA from ... electrophoresis in TAE, TBE, MOPS, or phosphate ... in the TAE, TBE, MOPS, and phosphate ...
... Preparation contains a unique β-agarose digesting enzyme ... of intact DNA and RNA from low ... in TAE, TBE, MOPS, or phosphate buffers. ... the TAE, TBE, MOPS, and phosphate electrophoresis ...
... Perhaps sheer in-house demand is causing shortages ... your precious antibody. This can cause unwanted ... • Receive royalties for your hard work ... let us build it up and market ...
Biology Products: